Overview Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception Status: Completed Trial end date: 2005-10-01 Target enrollment: Participant gender: Summary To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen. Phase: Phase 3 Details Lead Sponsor: Wyeth is now a wholly owned subsidiary of PfizerTreatments: EstradiolEstradiol 17 beta-cypionateEstradiol 3-benzoateEstradiol valerateEthinyl EstradiolEthinyl estradiol, levonorgestrel drug combinationLevonorgestrelPolyestradiol phosphate